APP and early-onset autosomal dominant Alzheimer disease: They concluded that through PPARγ activation, rosiglitazone enhanced hippocampal cognitive function from regulation of presynaptic vesicular proteins critical for proper glutamatergic neurotransmitter release (SNARE-associated proteins), synaptic transmission, and short-term plasticity in Tg2576 APP mice, a model of Alzheimer’s disease[32].